PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

100, 400,



NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

Тo:

KAWAMIYA, Osamu AOYAMA & PARTNERS IMP Building 3-7, Shiromi 1-chome Chuo-ku, Osaka-shi Osaka 5400001



	JAPON
Date of mailing (day/month/year) 28 September 2006 (28.09.2006)	
Applicant's or agent's file reference 665078	IMPORTANT NOTIFICATION
International application No. PCT/JP2005/004098	International filing date (day/month/year) 09 March 2005 (09.03.2005)
Applicant Kyoto Uni	versity et al
1. Transmittal of the translation to the applicant.	
The International Bureau transmits herewith a copy of the patentability (Chapter I).	e English translation of the international preliminary report on
The International Bureau transmits herewith a copy of th patentability (Chapter II).	e English translation of the international preliminary report on .
2. Transmittal of the copy of the translation to the designated or e	elected Offices.
The International Bureau notifies the applicant that copies of that Offices requiring such translation:	translation have been transmitted to the following designated or elected
None	
The following designated or elected Offices, having waived the retranslation from the International Bureau only upon their request:	equirement for such a transmittal at this time, will receive copies of that
EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU	, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, I, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, IZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, VN, YU, ZA, ZM, ZW
3. Reminder regarding translation into (one of) the official langua	ege(s) of the elected Office(s).
The applicant is reminded that, where a translation of the international contain a translation of any annexes to the international prelin	ional application must be furnished to an elected Office, that translation ninary report on patentability (Chapter II).
It is the applicant's responsibility to prepare and furnish suapplicable time limit (Rule 74.1). See Volume II of the PCT Applicable time limit (Rule 74.1).	ch translation directly to each elected Office concerned within the plicant's Guide for further details.

The International Bureau of WIP	O
34, chemin des Colombettes	
1211 Geneva 20, Switzerland	

Authorized officer

Masashi Honda

1 hay to

Facsimile No. +41 22 338 82 70

4

Facsimile No. +41 22 338 82 70

PATENT COOPERATION TREATY

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 665078	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/JP2005/004098	International filing date (day/month/year) 09 March 2005 (09.03.2005)	Priority date (day/month/year) 09 March 2004 (09.03.2004)	
International Patent Classification (8th See relevant information in Form P	n edition unless older edition indicated) PCT/ISA/237		
Applicant Kyoto University			

1.	This international preliminary re International Searching Authorit	port on patentability (Chapter I) is issued by the International Bureau on behalf of the y under Rule 44 $bis.1(a)$.
2.	This REPORT consists of a total	of 7 sheets, including this cover sheet.
	In the attached sheets, any refere to the international preliminary r	ence to the written opinion of the International Searching Authority should be read as a reference eport on patentability (Chapter I) instead.
3.	This report contains indications i	relating to the following items:
	Box No. I	Basis of the report
	Вох №. П	Priority
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	Box No. IV	Lack of unity of invention
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	Box No. VI	Certain documents cited
	Box No. VII	Certain defects in the international application
	Box No. VIII	Certain observations on the international application
4.	The International Bureau will co not, except where the applicant r date (Rule 44bis .2).	mmunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but nakes an express request under Article 23(2), before the expiration of 30 months from the priority

	Date of issuance of this report 19 September 2006 (19.09.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Masashi Honda
Facsimile No. +41 22 338 82 70	e-mail: pt08@wipo.int

Form PCT/IB/373 (January 2004)

PATENT COOPERATION TREATY

TRANSLATION INTERNATIONAL SEARCHING AUTHORITY То: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION 665078 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/JP2005/004098 09.03.2005 09.03.2004 International Patent Classification (IPC) or both national classification and IPC Applicant Kyoto University This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Name and mailing address of the ISA/JP Authorized officer Facsimile No. Telephone No.

International application No.
PCT/JP2005/004098

Box	x No. 1 Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
	This opinion has been established on the basis of a translation from the original language into the following language . which is the language of a translation furnished for the purposes of international search (under
	Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
	a. type of material
	a sequence listing
	table(s) related to the sequence listing
ŀ	b. format of material
	in written format
	in computer readable form
	c. time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:

International application No.
PCT/JP2005/004098

Box No. I	II Non-establishment of opini	on with regard to novelty, inventive step and industrial applicability
	ions whether the claimed invention a have not been examined in respect of:	appears to be novel, to involve an inventive step (to be non obvious), or to be industrially
	the entire international application	
\boxtimes	claims Nos. 10-13	
becaus	se:	
\boxtimes	the said international application, or trelate to the following subject matter	the said claims Nos. 10-13 which does not require an international preliminary examination (specify):
		0-13 relate to a method for treatment of the human body by therapy, international preliminary examination in accordance with PCT Rule
	the description, claims or drawings (i are so unclear that no meaningful opi	ndicate particular elements below) or said claims Nos. nion could be formed (specify):
	the claims, or said claims Nos. by the description that no meaningful	are so inadequately supported opinion could be formed.
\boxtimes	no international search report has bee	en established for said claims Nos. 10~13
		uence listing does not comply with the standard provided for in Annex C of the Administrative
	the written form	has not been furnished
		does not comply with the standard
	the computer readable form	has not been furnished does not comply with the standard
		Ind/or amino acid sequence listing, if in computer readable form only, do not comply with the n Annex C-bis of the Administrative Instructions.
	See Supplemental Box for further det	•

International application No.

WRIT INTERNATION	TEN OPINION NAL SEARCHI			TY		P	CT/JP:	2005/00	4098
Box No. V Reasoned statement citations and expla					to novelty, ir	ventive step	or indust	rial applicabili	ty;
. Statement									
Novelty (N)	Claims]	L-9,	14						YE
	Claims								NO
Inventive step (IS)	Claims 1	1 – 9	1 4						YE
	Claims								1E
Industrial applicability (IA)									
moustral appreadinty (1A)	Claims							.	YE NO
	Claims				•				NC
. Citations and explanations:					•				
Document 5: JP, 2002-52 Document 6: JP, 2002-52 Document 7: ROBLEDC CXCR4 on human melar 276 (48), pp. 45098-105 <explanation> The inventions of claims cited in the ISR. Documents 1-7 do not de metastatic and other cancart.</explanation>	13388, A (TO M M et al noma cells., 1-9 and 14 escribe the i	Theod Exp . Journ appe	or-Kooressional of in ar to in ar to in	cher Ins n of fur piologic nvolve a	stitute), 8 nctional c cal chemi an inventi	May, 200 hemokine stry, 30 N ive step in	2 (08.05) recepto fovember view o	ors CXCR3 er, 2001 (30 f document	0.11.01 s 1-7 t of

International application No.

PCT/JP2005/004098

Certain published documents (Rule 43bis.1 and			
Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid clai (day/month/year)
JP 2005-132761 A [EX, EY]	26.05.2005	29.10.2003	
Non-written disclosures (Rule 43bis.1 and 70.9)			
			ate of written disclosure
Kind of non-written disclosure	Date of non-written of (day/month/ve		ing to non-written disclosure (day/month/year)
	•		
			•

International application No.
PCT/JP20:0-5/004098

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1, 5, 6 and 8 relate to medical compositions to treat cancer which contain, as active of ingredients, compounds defined by their desired properties, for example, "a CXCR3 inhibitor", "a CXCR3-mediated signal transduction inhibitor in cancer cells", "a CXCR3 expression inhibitor", "a CXCR3 antagonist and an antibody against a CXCR3 ligand and a fragment thereof having an antigen-binding activity", "a CXCR3 antisense, siRNA and a CXCR3 expression inhibitor", "a mutant of a CXCR3 ligand and a ligand-binding inhibitor." And claims 1, 5, 6 and 8 include all compounds having such properties, but only a very small portion of the claimed compounds are supported by the description in the sense of PCT Article 6, and disclosed in the sense of PCT Article 5.

And for "CXCR3 inhibitor", no scope of compounds having such properties can be specified even when considering the common general technical knowledge at the time of the application. Therefore, claims 1, 5, 6 and 8 do not fulfill the requirement of clarity according to PCT Article 6.